Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.
Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.
milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.
Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.
Mayroon kaming maraming mga pabrika na may mataas na kalidad na may malalim na pakikipagtulungan, na maaaring magbigay sa iyo ng mga de-kalidad na produkto at mapagkumpitensyang presyo. At makakapagbigay din kami ng mga diskwento para sa maramihang pagbili. At nakikipagtulungan kami sa maraming propesyonal na kumpanyang nagpapasa ng kargamento, maaaring makapaghatid ng mga produkto nang ligtas at maayos sa iyong mga kamay. Ang oras ng paghahatid ay humigit-kumulang 3-20 araw pagkatapos ng kumpirmasyon ng pagbabayad.
Pagsusuri
|
Pagtutukoy
|
Resulta
|
Test method
|
Physical Description
|
|
|
|
Hitsura
|
White Powder
|
White Powder |
Visual
|
Ang amoy
|
Characteristic
|
Characteristic
|
Organoleptic
|
Particle size
|
90% pass 80 mesh
|
90% pass 80 mesh
|
80 Mesh Screen
|
Chemical Tests
|
|
|
|
Assay (Lutein)
|
99%
|
90.15%
|
HPLC
|
Loss on drying
|
5.0% Max
|
1.82%
|
5g/105ºC/2hrs
|
Ash Contents
|
5.0% Max
|
1.12%
|
2g/525ºC/3hrs
|
Residual Solvents
|
50.0 ppm, Only Ethanol
|
<30.0 ppm
|
/
|
Heavy metals
|
5.0 ppm Max
|
<3.0 ppm
|
AAS
|
Lead
|
3.0 ppm Max
|
<1.0 ppm
|
AAS
|
Arsenic
|
3.0 ppm Max
|
<1.0 ppm
|
AAS
|
Microbiology Control
|
|
|
|
Total Bacteria Count
|
1,000cfu/g Max
|
<280cfu/g
|
AOAC
|
Yeast & Mold
|
100cfu/g Max
|
<10cfu/g
|
AOAC
|
Coliform
|
30.0 MPN/g Max
|
<3.0 MPN/g
|
AOAC
|
Konklusyon
|
Complies with the standards.
|
||
General Status
|
Non-GMO, ISO Certificated.
|
Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.
1. Ikaw ba ay isang pabrika o isang kumpanya ng kalakalan?
Kami ay isang compnay na nagsasama ng industriya at kalakalan, na nagbibigay ng one-stop na serbisyo. Maaaring tanggapin ang OEM.
2. Nagbibigay ka ba ng mga sample? Libre ba ito o dagdag?
Libreng sample. Ang bayad sa kargamento ng sample ay kailangang bayaran sa tabi mo.
3. Mayroon ka bang anumang mga sertipiko na may kaugnayan sa kontrol sa kalidad?
ISO 9001:2008 certification para matiyak ang kalidad.
4. Ano ang dapat kong ibigay para makakuha ng quotation?
Pls ipaalam sa amin ang uri ng produkto na kailangan mo, dami ng order, address at mga partikular na kinakailangan. Ang quotation ay gagawin para sa iyong sanggunian sa oras.
5. Anong uri ng paraan ng pagbabayad ang gusto mo? Anong uri ng mga tuntunin ang tinatanggap?
Tinanggap na Mga Tuntunin sa Paghahatid: FOB,CFR,CIF,EXW;
Tinanggap na Pera ng Pagbabayad:USD;
Tinanggap na Uri ng Pagbabayad: T/T,Western Union; Paypal, Trade Assurance.
Wikang Sinasalita:Ingles.
Mga kategorya ng produkto